TAK Stock Analysis: Buy, Sell, or Hold?
TAK - Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
$19.67
0.22 (1.13%)
▲
5d:
+5.02%
30d:
+3.25%
90d:
+15.37%
WAIT
LOW Confidence
Analysis Updated: Oct 16, 2026 12:00 AM ET
Earnings: Oct 29, 2026
11d
Get Alerted When TAK Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: TAK shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: TAK shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$36.99
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$22.97
14.4% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 0.2x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: TAK is currently trading at $19.67, which is considered extended relative to its 30-day fair value range of $18.15 to $19.03. The stock's valuation (Forward PE: 0.2) is in line with its historical norms (0.2). At these levels, the market is pricing in 5.5% annual earnings growth.
Technical Outlook: Technically, TAK is in a strong uptrend. The price is approaching resistance at $19.89. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: TAK scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $22.77 (+15.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, TAK is in a strong uptrend. The price is approaching resistance at $19.89. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: TAK scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $22.77 (+15.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$18.15 -
$19.03
Company Quality Score
42/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
29.5%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($22.77)
- BULLISH: Expecting earnings turnaround to 5.5% growth with 10.2% revenue growth
- WARNING: Composite score 42/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$18.15 -
$19.03
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$17.75
Resistance Level
$19.89
Current Trend
Strong Uptrend
Technical data as of
Oct 16, 2026
Fundamental Context
Forward P/E (Next Year Est.)
0.21
Wall Street Target
$22.77
(+15.7%)
Revenue Growth (YoY)
10.2%
Earnings Growth (YoY)
-9.8%
Profit Margin
-3.5%
Valuation Premium vs History
+5.5% premium
PE vs Historical
0.2 vs 0.2
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+5.5%
(market-implied from PE analysis)
1-Year Target
$20.75
(+6%)
2-Year Target
$21.89
(+11%)
3-Year Target
$23.10
(+17%)
3-Yr Target (if PE normalizes)
(PE: 0→0)
PE COMPRESSION
$22.31
(+13%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 19.9, Growth: 93.0%)
$6366.41
(+32266%)
Base:
(SPY PE: 0.2, Growth: 93.0%)
$66.39
(+238%)
Bear:
(PE: 0.2, Growth: 93.0%)
$56.43
(+187%)
Share & Embed Analysis
Last updated: October 17, 2026 7:55 AM ET
Data refreshes hourly during market hours. Next update: 8:55 AM
Data refreshes hourly during market hours. Next update: 8:55 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TAK showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
29 analysts |
$207 | 58 HOLD |
|
ALKS
Alkermes Plc |
STRONG BUY
19 analysts |
$57 | 64 BUY |
|
ELAN
Elanco Animal Health |
STRONG BUY
16 analysts |
$31 | 53 HOLD |
|
AMLX
Amylyx Pharmaceuticals I… |
STRONG BUY
12 analysts |
$42 | 55 HOLD |
|
HCM
HUTCHMED DRC |
STRONG BUY
13 analysts |
$22 | 55 HOLD |
